Down 43% on Nov 9 while the S&P 500 rose 2%.
−2Volatility
New listing, trading since Jun 16, 2026. 103 trading days so far, so 3 of the 14 chart checks wait for more history.
Follow FTH's trial news. Pro members can get an alert when Faeth Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 21.4% a day with no profit behind it |
| Latest filing | 8-K, Nov 9 |
After its last 2 reports it closed -2.3% on average, higher 1 of 2 times.
About 16 quarters
CFO Brian C Stephenson bought 13,634 shares on Jul 1. 3 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
FTH is #156 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 156 |
Expected to report Thu Feb 18, before the open (in 100 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.79 a share, from $3.62.
“The increase in R&D expenses was primarily driven by development costs for PIKTOR and other Faeth programs, including clinical trial, chemistry, manufacturing and controls (CMC) and preclinical expenses, together with higher personnel costs, partially offset by lower clinical trial costs for legacy Sensei programs.”
FTH's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in G&A expenses was primarily attributable to higher personnel costs and increased external administrative fees, primarily legal fees.”
From its results filing (SEC filing · Nov 3)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | -2.0% | +2.2% | -34.1% |
| Aug 4, 2026 | +0.6% | -6.7% | +4.5% |
RSI 29.4, MACD below signal. Not scored.
2 insiders bought $1.2M across 23 filings, and one insider sold $501K across 2 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
FTH scores -1 today, which Breakaway calls Poor. It is #156 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 43% on Nov 9 while the S&P 500 rose 2%. Cash lasts about 16 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
FTH scores -1 today, which Breakaway calls Poor (below zero). That is #156 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind FTH's -1.
2 insiders bought $1.2M across 23 filings, and one insider sold $501K across 2 filings, in the last 6 months. The newest is Brian C. Stephenson, Chief Financial Officer, who bought $106K on Jun 30. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.